This is Thomas Sullivan - Policy & Medicine Writing Staff's Typepad Profile.
Join Typepad and start following Thomas Sullivan - Policy & Medicine Writing Staff's activity
Join Now!
Already a member? Sign In
Thomas Sullivan - Policy & Medicine Writing Staff
Columbia, Maryland
Former political consultant who founded Rockpointe, Inc. a bio-medical education company in 1995.
Interests: marketing, politics, baseball, cycling, medicine, university of florida sports, medical education, track and cross country, driving kids to various practices
Recent Activity
Image
On Tuesday, June 27, 2017, California Senate Bill 790 will be heard in the Assembly Committee on Health, with limited testimony allowed per side. We have previously written about the bill, noting that the bill passed the California Senate back... Continue reading
Posted 1 hour ago at Policy and Medicine
Image
In constructively bringing an end to a False Claims Act (“FCA”) whistleblower suit alleging Genentech, Inc. (“Genentech”) of defrauding Medicare by way of concealing substantive health care analytics data involving purported side effects of the company’s cancer drug Avastin, the... Continue reading
Posted 1 hour ago at Policy and Medicine
Image
For the past three years, Amgen has faithfully released an annual “Trends in Biosimilars Report.” This year’s report highlights various viewpoints from experts in the United States reimbursement community, as well as information on current physician and patient perceptions. While... Continue reading
Posted 3 days ago at Policy and Medicine
Image
Lately pharmaceutical marketing has been under increasing attack at both state and federal governmental levels. Now Chicago has joined D.C. in the attempt to regulate pharmaceutical representatives. Billed by Chicago Mayor Rahm Emanuel as a measure to curb opioid addiction,... Continue reading
Posted 3 days ago at Policy and Medicine
Image
The Centers for Medicare and Medicaid Services (CMS) finally mailed out letters to medical practices, providing clinicians with their participation status in the Merit-based Incentive Payment System (MIPS). MIPS is one of two payment tracks within the Medicare Access and... Continue reading
Posted 4 days ago at Policy and Medicine
Image
On Tuesday, the Centers for Medicare & Medicaid Services (CMS) released the long-anticipated proposed rule updating the Quality Payment Program – the program implementing the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) – for 2018. The rule continues... Continue reading
Posted 5 days ago at Policy and Medicine
Image
As cross-border business and technology advances, the European Union’s need to address data privacy protection continually rises. The General Data Protection Regulation will soon be enforceable and undoubtedly will have impact on how pharmaceutical and medical device companies conduct clinical... Continue reading
Posted 5 days ago at Policy and Medicine
Image
Ohio Attorney General Mike DeWine filed a lawsuit against five drug companies on May 31, 2017, alleging that they fueled the opioid addiction crisis by misrepresenting the addictive risks of the painkillers they manufacture. The lawsuit, filed against Purdue Pharma... Continue reading
Posted 6 days ago at Policy and Medicine
Image
Patient assistance programs have been in the spotlight for the past few years as the drug pricing controversy comes to a head. This article outlines some of the recent subpoenas, with focus on the most recent subpoena to make the... Continue reading
Posted 6 days ago at Policy and Medicine
Image
We have written several articles on the Nevada bill that requires patient advocacy organizations to report all payments they receive from industry. The bill requires all payments be reported, irrespective of the nature of the payment (i.e., research, education, donations,... Continue reading
Posted 7 days ago at Policy and Medicine
Image
Achieving patient adherence to prescribed medication through clinical educator programs is not a new concept. Neither is the U.S. Office of Inspector General of the Health and Human Services longstanding concern of the inherent issues these programs pose when offered... Continue reading
Posted 7 days ago at Policy and Medicine
Image
California has not been known to be the most “business friendly” state in the union in recent history. We recently wrote about legislation passed in the California state senate that was intended to restrict pharmaceutical companies from giving gifts and... Continue reading
Posted Jun 16, 2017 at Policy and Medicine
Image
On Tuesday, June 20th, qordata is hosting a panel discussion webinar on “Learning From CMS Spend Submission.” The webinar will run from 11:00 am EST – 12:00 pm EST and will include discussion from Chrissy Bradshaw of Porizo, April Pierce... Continue reading
Posted Jun 16, 2017 at Policy and Medicine
Image
FDA Commissioner Scott Gottlieb – sworn in on May 11, 2017 – has established a steering committee to address the opioid crisis and advise regulators on such steps as prescription limits. Gottlieb, who said overuse of painkillers was his top... Continue reading
Posted Jun 15, 2017 at Policy and Medicine
Image
After being vetoed the week before the Nevada State Legislature passed a bill to combat drug prices but also requires patient advocacy organizations to report all payments they receive from industry regardless of the nature of payment including research, education,... Continue reading
Posted Jun 14, 2017 at Policy and Medicine
Image
As we are all aware, many states have started to take notice of the heat industry is under for its interactions with physicians. In order to “jump on the bandwagon,” many states have started to introduce legislation to place restrictions... Continue reading
Posted Jun 14, 2017 at Policy and Medicine
Image
President Donald Trump’s FY 2018 budget proposal seeks a renegotiation of user fee deals made over the last two years to make up for roughly a 30% decrease in the United States Food and Drug Administration (FDA) budget. The budget,... Continue reading
Posted Jun 13, 2017 at Policy and Medicine
Image
On Friday, May 5, 2017, the Alliance for Health Reform held a briefing “The Individual Market at a Crossroads: Health Insurance in 2017 and Beyond.” During the briefing, a panel of experts discussed the history of the individual (non-group) healthcare... Continue reading
Posted Jun 12, 2017 at Policy and Medicine
Image
In a March hearing before the House Energy & Commerce Committee, FDA’s Jeffery Shuren announced the FDA’s Office of Regulatory Affairs (ORA), would undergo a program realignment. As the FDA notes, on September 6, 2013, then Commissioner Margaret Hamburg, M.D.,... Continue reading
Posted Jun 9, 2017 at Policy and Medicine
Image
In April 2017, the Department of Health (DOH) in the District of Columbia (D.C.) quietly posted Frequently Asked Questions (FAQs) regarding AccessRx reporting requirements. AccessRx requires manufacturers and labelers of prescription drugs that are dispensed in D.C. who engage in... Continue reading
Posted Jun 8, 2017 at Policy and Medicine
Image
Some of our loyal readers may remember an article we ran last week about the Nevada state legislature passing one of the country’s strongest pharma transparency bills. Last Friday the Governor veto'ed the original bill but the legislature then amended... Continue reading
Posted Jun 7, 2017 at Policy and Medicine
Image
On Thursday, May 11, 2017, the Senate Health, Education, Labor, and Pensions (HELP) Committee advanced an amended version of the Food and Drug Administration Reauthorization Act (FDARA) to the Senate floor by a 21-2 vote during an executive session. Senator... Continue reading
Posted Jun 6, 2017 at Policy and Medicine
Image
Recently, industry group Pharmaceutical Research and Manufacturers of America (PhRMA) expelled twenty-two members who did not meet new criteria for membership. On May 9, 2017, the PhRMA board of directors approved the new criteria for membership, which requires biopharmaceutical companies... Continue reading
Posted Jun 5, 2017 at Policy and Medicine
Image
Late last week, Maryland Governor Larry Hogan allowed a law targeted at preventing generic drug prices from increasing by too much. The law imposes fines on generic drug makers who raise the wholesale acquisition cost (WAC) of their products by... Continue reading
Posted Jun 2, 2017 at Policy and Medicine
Image
Democrats in Nevada’s state senate are posturing that they have passed one of the country’s strongest pharma transparency bills targeting diabetes drug prices. Senate Bill 265, approved mid-May, would force diabetes drug makers to disclose information on their insulin pricing,... Continue reading
Posted Jun 1, 2017 at Policy and Medicine